N-Epsilon-(carboxymethyl)lysine is unable to induce endothelial dysfunction but is able to attenuate AGEs-induced endothelium damage in human umbilical vein endothelial cells

Pharmazie

Volumn 68, Issue 4, 2013, Pages 251-256

  Feng, Liang ^a   Zhu, Mao Mao ^a   Zhang, Ming Hua ^a   Jia, Xiao Bin ^a  

^a KEY LABORATORY OF NEW DRUG DELIVERY SYSTEM OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LYSINE; N EPSILON (CARBOXYMETHYL)LYSINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ACRIDINE ORANGE; ADULT; ALGORITHMS; APOPTOSIS; DATA INTERPRETATION, STATISTICAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ETHIDIUM; FEMALE; FLUORESCENCE POLARIZATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYSINE; PREGNANCY; TETRAZOLIUM SALTS; THIAZOLES; TRANSFORMING GROWTH FACTOR BETA1; UMBILICAL VEINS;

EID: 84876237141     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2765     Document Type: Article

References (43)

1. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW(1999) The myeloperoxidase system of human phagocytes generates Nepsilon- (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104: 103-113.
2. Aronson D (2002) Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 59: 297-301.
3. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105: 816-822.
4. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H,Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50: 2792-2808.
5. Bigl K, Schmitt A, Meiners I, Münch G, Arendt T (2007) Comparison of results of the CellTiter Blue, the tetrazolium (3-[4,5-dimethylthioazol- 2-yl]-2,5-diphenyl tetrazolium bromide), and the lactate dehydrogenase assay applied in brain cells after exposure to advanced glycation endproducts. Toxicol In Vitro 21: 962-971.
6. Boulanger E,WautierMP, Gane P, Mariette C, Devuyst O,Wautier JL (2004) The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 19: 2208-2216.
7. Buetler TM, Leclerc E, Baumeyer A, Latado H, Newell J, Adolfsson O, ParisodV, Richoz J, Maurer S, Foata F, Piguet D, Junod S, HeizmannCW, Delatour T (2008) N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 52: 370-378.
8. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA (2002) RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 71: 433-444.
9. Feng L, Jia XB, Jiang J, Zhu MM, Chen Y, Tan XB, Shi F (2010) Combination of active components enhances the efficacy of Prunella in prevention and treatment of lung cancer. Molecules 15: 7893-7906.
10. Franke S,Dawczynski J, Strobel J, Niwa T, Stahl P, SteinG(2003) Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg 29: 998-1004.
11. Fritz G (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 36: 625-632.
12. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1996) The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986.
13. Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE (2008) SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 28: 665-671.
14. Gasic-Milenkovic J, Loske C, Deuther-ConradW, Münch G (2001) Protein "AGEing"-cytotoxicity of a glycated protein increases with its degree of AGE-modification. Z Gerontol Geriatr 34: 457-460.
15. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M (2009) The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58: 1659-1667.
16. Ghanem AA, Elewa A, Arafa LF (2011) Pentosidine and N- carboxymethyllysine: biomarkers for type 2 diabetic retinopathy. Eur J Ophthalmol 21: 48-54.
17. Goldin A, Beckman JA, Schmidt AM, CreagerMA(2006) Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 14: 597-605.
18. Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M. 2011. Binding studies of truncated variants of the A- peptide to the V-domain of the RAGE receptor reveal A- residues responsible for binding. Biochim Biophys Acta 1814: 592-609.
19. Huttunen HJ, Fages C,Kuja-Panula J, Ridley AJ, RauvalaH(2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811.
20. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)- (carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem Oct 274: 31740-31749.
21. Kneyber MC, Gazendam RP, Niessen HW, Kuiper JW, Dos Santos CC, Slutsky AS, Plötz FB (2009) Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation. Crit Care 13: R87.
22. LeeBW, Chae HY, Kwon SJ, Park SY, Ihm J, Ihm SH (2010) RAGE ligands induce apoptotic cell death of pancreatic -cells via oxidative stress. Int J Mol Med 26: 813-818.
23. Li Y, Wang MY, Fan XS, Qi X, Chen Y, Zhang H, Zhao QC (2010) Effect of San-ao Decoction, a traditional Chinese prescription, on IL- 4 treated normal human bronchial epithelium. J Ethnopharmacol 131: 104-109.
24. Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW (2006) Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxalmodified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 95: 320-328.
25. Matsui H, Suzuki M, Tsukuda R, Iida K, Miyasaka M, Ikeda H (1996) Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat,Wistar fatty. Diabetes Res Clin Pract 32: 1-9.
26. Matsumoto T, Ozawa Y, Taguchi K, Kobayashi T, Kamata K (2010) Diabetes-associated changes and role of Nepsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. Peptides 31: 346-353.
27. Nienhuis HL,Westra J, Smit AJ, Limburg PC, Kallenberg CG, BijlM(2009) AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity 42: 302-304.
28. Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, Burrell LM, Cooper ME, Forbes JM (2010) Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78: 287-295.
29. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 57: 1874-1880.
30. Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S (2010) Pigment epithelium-derived factor inhibits advanced glycation end productsinduced retinal vascular permeability. Biochimie 92: 1040-1051.
31. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end products: a review. Diabetologia 44: 129-146.
32. Sjögren P, Basta G, de Caterina R, Rosell M, Basu S, Silveira A, de Faire U, Vessby B, Hamsten A, Hellenius ML, Fisher RM (2007) Markers of endothelial activity are related to components of the metabolic syndrome, but not to circulating concentrations of the advanced glycation end-product N epsilon-carboxymethyl-lysine in healthy Swedish men. Atherosclerosis 195(2): e168-e175.
33. Southern L, Williams J, Esiri MM (2007) Immunohistochemical study of Nepsilon- carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol 16: 1-8.
34. Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol 78: 539-552.
35. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666.
36. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z (2000) Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 59: 1094-1105.
37. Tochino Y, Kanazawa H, Ichimaru Y, Asai K, Kyoh S, Hirata K (2007) Nepsilon-(carboxymethyl)lysine, a major advanced glycation end product in exhaled breath condensate as a biomarker of small airway involvement in asthma. J Asthma 44: 861-866.
38. Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE (2004) Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxinfree albumin-derived advanced glycation end products. Diabetologia 47: 844-852.
39. van DeutekomAW, NiessenHW, Schalkwijk CG, Heine RJ, Simsek S (2008) Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus. Eur J Endocrinol 158: 655-660.
40. Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E (2000) Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 43: 1385-1388.
41. Xu Y, Toure F, Qu W, Lin L, Song F, Shen X, Rosario R, Garcia J, Schmidt AM, Yan SF (2010) Advanced glycation end product (AGE)- receptor forAGE(RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 285: 23233-23240.
42. Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B (2010) Blockade of PKCbeta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol 10: 1552-1559.
43. Yoshinaga E, Kawada A, Ono K, Fujimoto E,Wachi H, Harumiya S, Nagai R, Tajima S (2011) N(-)-(carboxymethyl)lysine modification of elastin alters its biological properties: implications for the accumulation of abnormal elastic fibers in actinic elastosis. J Invest Dermatol 132: 315-323.